Biomea Fusion (Nasdaq:BMEA) - Prezzo delle azioni, notizie e analisi

BMEA Panoramica delle azioni

Biomea Fusion, Inc. è un'azienda biofarmaceutica in fase clinica che si concentra sulla scoperta e sullo sviluppo di farmaci covalenti a piccole molecole per il trattamento di pazienti affetti da tumori e malattie metaboliche geneticamente definite. Maggiori dettagli

BMEA analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 89.92% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Ha meno di 1 anno di pista di cassa

Prezzo delle azioni volatile negli ultimi 3 mesi

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Biomea Fusion, Inc. Concorrenti

Fate Therapeutics

NasdaqGM:FATE

US$305.2m

Zentalis Pharmaceuticals

NasdaqGM:ZNTL

US$248.0m

Benitec Biopharma

NasdaqCM:BNTC

US$228.7m

Eledon Pharmaceuticals

NasdaqCM:ELDN

US$253.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Biomea Fusion
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$7.02
Massimo di 52 settimane	US$22.74
Minimo di 52 settimane	US$3.61
Beta	-0.43
1Variazione di 1 mese	-43.43%
Variazione a 3 mesi	-7.87%
Variazione di 1 anno	-44.94%
3Variazione a 3 anni	-40.15%
Variazione a 5 anni	n/a
Variazione dall'IPO	-62.26%

Notizie e aggiornamenti recenti

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Sep 30

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Rendimenti per gli azionisti

	BMEA	US Biotechs	US Mercato
7D	11.8%	4.3%	1.6%
1Y	-44.9%	18.8%	32.3%

Ritorno vs Industria: BMEA ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18.8 % nell'ultimo anno.

Rendimento vs Mercato: BMEA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.3 % nell'ultimo anno.

Volatilità dei prezzi

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement	10.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di BMEA è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di BMEA è diminuita da 17% a 11% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2017	107	Thomas Butler	biomeafusion.com

Biomea Fusion, Inc. è una società biofarmaceutica in fase clinica che si concentra sulla scoperta e sullo sviluppo di farmaci covalenti a piccole molecole per il trattamento di pazienti con tumori geneticamente definiti e malattie metaboliche. Il suo candidato principale è BMF-219, un inibitore covalente della menina per il trattamento di pazienti affetti da tumori liquidi e solidi e da diabete di tipo 2. La società è stata costituita nel 2017 e ha sede a Redwood City, in California.

Biomea Fusion, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Biomea Fusion con la sua capitalizzazione di mercato?
BMEA statistiche fondamentali
Capitalizzazione di mercato	US$249.68m
Guadagni(TTM)	-US$144.01m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.8x

Rapporto P/E

BMEA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BMEA Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$144.01m
Guadagni	-US$144.01m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.97
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato BMEA nel lungo periodo?

Vedi performance storica e confronto

BMEA Panoramica delle azioni

Premi

Analisi del rischio

Biomea Fusion, Inc. Concorrenti

NasdaqGM:FATE

US$305.2m

NasdaqGM:ZNTL

US$248.0m

NasdaqCM:BNTC

US$228.7m

NasdaqCM:ELDN

US$253.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Recent updates

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022